DNA methylation in APOE: The relationship with Alzheimer’s and with cardiovascular health

Jure Mur; Daniel L McCartney; Rosie Walker; Archie Campbell; Mairead Bermingham; Stewart Morris; David Porteous; Andrew McIntosh; Ian Deary; Kathryn Evans; Riccardo Marioni

doi:10.1002/trc2.12026

DNA methylation in APOE: The relationship with Alzheimer’s and with cardiovascular health

Jure Mur, Daniel L McCartney, Rosie Walker, Archie Campbell, Mairead Bermingham, Stewart Morris, David Porteous, Andrew McIntosh, Ian Deary, Kathryn Evans, Riccardo Marioni

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

INTRODUCTION: Genetic variation in the apolipoprotein E (APOE) gene is associated with Alzheimer’s disease (AD) and risk factors for cardiovascular disease (CVD). DNA methylation at APOE has been associated to altered cognition and AD. It is unclear if epigenetic marks could be used for predicting future disease.

METHODS: We assessed blood-based DNA methylation at 13 CpGs in the APOE gene in 5828 participants from the Generation Scotland (GS) cohort. Using linear regression, we examined the relationship between APOE methylation, cognition, cholesterol, and the risks for AD and CVD.

RESULTS: DNA methylation at two CpGs was associated with the ratio/quotient of total cholesterol and HDL cholesterol, but not with cognition, or the risks of AD or CVD.

DISCUSSION: APOE methylation could be involved in the levels of blood cholesterol, but there is no evidence for the utility of APOE methylation as a biomarker for predicting AD or CVD.

Original language	English
Journal	Alzheimer's and Dementia: Translational Research and Clinical Interventions
Volume	6
Issue number	1
Early online date	27 Apr 2020
DOIs	https://doi.org/10.1002/trc2.12026
Publication status	E-pub ahead of print - 27 Apr 2020

Keywords / Materials (for Non-textual outputs)

APOE
DNA methylation
Alzheimer’s disease
cardiovascular disease
cholesterol
biomarker

Access to Document

10.1002/trc2.12026

MurEtalA&DTR&CI2020DNAMethylationInAPOEFinal published version, 1.62 MBLicence: Creative Commons: Attribution (CC-BY)

Omics prediction of Alzheimer's disease
Marioni, R.
UK-based charities
1/10/17 → 31/01/21
Project: Research
The Disconnected Mind Phase 3
Cox, S. & Deary, I.
1/04/16 → 31/03/23
Project: Research
RA2662 Centre for Cognitive Ageing and Cognitive Epidemiology Phase 2.
Porteous, D.
1/09/13 → 31/08/19
Project: Research

Andrew McIntosh
- Deanery of Clinical Sciences - Chair of Biological Psychiatry
- Centre for Clinical Brain Sciences
- Edinburgh Neuroscience
Person: Academic: Research Active

Cite this

Mur, J., McCartney, D. L., Walker, R., Campbell, A., Bermingham, M., Morris, S., Porteous, D., McIntosh, A., Deary, I., Evans, K., & Marioni, R. (2020). DNA methylation in APOE: The relationship with Alzheimer’s and with cardiovascular health. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 6(1). Advance online publication. https://doi.org/10.1002/trc2.12026

@article{08d0803fa88645229d463f2bc9e26a98,

title = "DNA methylation in APOE: The relationship with Alzheimer{\textquoteright}s and with cardiovascular health",

abstract = "INTRODUCTION: Genetic variation in the apolipoprotein E (APOE) gene is associated with Alzheimer{\textquoteright}s disease (AD) and risk factors for cardiovascular disease (CVD). DNA methylation at APOE has been associated to altered cognition and AD. It is unclear if epigenetic marks could be used for predicting future disease. METHODS: We assessed blood-based DNA methylation at 13 CpGs in the APOE gene in 5828 participants from the Generation Scotland (GS) cohort. Using linear regression, we examined the relationship between APOE methylation, cognition, cholesterol, and the risks for AD and CVD. RESULTS: DNA methylation at two CpGs was associated with the ratio/quotient of total cholesterol and HDL cholesterol, but not with cognition, or the risks of AD or CVD. DISCUSSION: APOE methylation could be involved in the levels of blood cholesterol, but there is no evidence for the utility of APOE methylation as a biomarker for predicting AD or CVD.",

keywords = "APOE, DNA methylation, Alzheimer{\textquoteright}s disease, cardiovascular disease, cholesterol, biomarker",

author = "Jure Mur and McCartney, {Daniel L} and Rosie Walker and Archie Campbell and Mairead Bermingham and Stewart Morris and David Porteous and Andrew McIntosh and Ian Deary and Kathryn Evans and Riccardo Marioni",

year = "2020",

month = apr,

day = "27",

doi = "10.1002/trc2.12026",

language = "English",

volume = "6",

journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",

issn = "2352-8737",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - DNA methylation in APOE

T2 - The relationship with Alzheimer’s and with cardiovascular health

AU - Mur, Jure

AU - McCartney, Daniel L

AU - Walker, Rosie

AU - Campbell, Archie

AU - Bermingham, Mairead

AU - Morris, Stewart

AU - Porteous, David

AU - McIntosh, Andrew

AU - Deary, Ian

AU - Evans, Kathryn

AU - Marioni, Riccardo

PY - 2020/4/27

Y1 - 2020/4/27

N2 - INTRODUCTION: Genetic variation in the apolipoprotein E (APOE) gene is associated with Alzheimer’s disease (AD) and risk factors for cardiovascular disease (CVD). DNA methylation at APOE has been associated to altered cognition and AD. It is unclear if epigenetic marks could be used for predicting future disease. METHODS: We assessed blood-based DNA methylation at 13 CpGs in the APOE gene in 5828 participants from the Generation Scotland (GS) cohort. Using linear regression, we examined the relationship between APOE methylation, cognition, cholesterol, and the risks for AD and CVD. RESULTS: DNA methylation at two CpGs was associated with the ratio/quotient of total cholesterol and HDL cholesterol, but not with cognition, or the risks of AD or CVD. DISCUSSION: APOE methylation could be involved in the levels of blood cholesterol, but there is no evidence for the utility of APOE methylation as a biomarker for predicting AD or CVD.

AB - INTRODUCTION: Genetic variation in the apolipoprotein E (APOE) gene is associated with Alzheimer’s disease (AD) and risk factors for cardiovascular disease (CVD). DNA methylation at APOE has been associated to altered cognition and AD. It is unclear if epigenetic marks could be used for predicting future disease. METHODS: We assessed blood-based DNA methylation at 13 CpGs in the APOE gene in 5828 participants from the Generation Scotland (GS) cohort. Using linear regression, we examined the relationship between APOE methylation, cognition, cholesterol, and the risks for AD and CVD. RESULTS: DNA methylation at two CpGs was associated with the ratio/quotient of total cholesterol and HDL cholesterol, but not with cognition, or the risks of AD or CVD. DISCUSSION: APOE methylation could be involved in the levels of blood cholesterol, but there is no evidence for the utility of APOE methylation as a biomarker for predicting AD or CVD.

KW - APOE

KW - DNA methylation

KW - Alzheimer’s disease

KW - cardiovascular disease

KW - cholesterol

KW - biomarker

U2 - 10.1002/trc2.12026

DO - 10.1002/trc2.12026

M3 - Article

SN - 2352-8737

VL - 6

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

IS - 1

ER -

DNA methylation in APOE: The relationship with Alzheimer’s and with cardiovascular health

Abstract / Description of output

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Projects

Omics prediction of Alzheimer's disease

The Disconnected Mind Phase 3

RA2662 Centre for Cognitive Ageing and Cognitive Epidemiology Phase 2.

Profiles

Andrew McIntosh

Cite this